We found that the combined treatment attenuated the expression of NF-κb and enhanced the expression of KLF-2 and ZO-1 compared with the single treatments (Figure 8A), resulting in reducing the leakage of new blood vessels in the capsule of the hematoma. The gene discussed is KLF2; the disease is hematoma.